Keywords
immunotherpay
novel agents
bispecific antibodies
antibody-drug conjugates
How to Cite
Abstract
Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody-drug conjugates, monoclonal antibodies with increased activity in antibody-dependent cytotoxicity and the so-called bispecific antibodies, immune-checkpoint inhibitors and CART cell therapies, all of them with an important success rate. Novel antibodies are being investigated in both aggressive and indolent
non-Hodgkin lymphoma with encouraging overall response rates including complete remissions.
These responses are seen even in heavily pre-treated patient populations such as those who have relapsed after CART-cell therapy. Potential toxicities include cytokine release syndrome, neurotoxicity and tumor flare, requiring a number of strategies to mitigate these risks. The following paragraphs describe these new antibodies, the main results published in the last 5 years, their mechanism of action, ongoing trials and main adverse events.
References
Awan FT, Lapalombella R, Trotta R, y col. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115 (6) 1204-1213.
Salles G, Duell J, González Barca E, y col. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020; 21 (7) 978-988.
Duell J, Maddocks KJ, González-Barca E y col. Longterm outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106 (9):2417-2426.
US Food & Drug Administration. FDA grants accelerated approval to Tafasitamab- cxix for diffuse large B-cell lymphoma. 2020;1-2.
Paillassa J, Safa F. Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer. Leuk Res Rep 2021 Dec 10;17:100282.
Rampotas A, Sangha G, Colllins G. Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma. Ther Adv Hematol; 2021, Vol. 12: 1-12.
Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context. 2021;10:2021-2-4.
Goebeler ME, Knop S, Viardot A y col. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. J Clin Oncol 2016; 34 (10) 1104-1111.
Viardot A, Goebeler ME, Hess G y col. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 2016; 127 (11) 1410-1416.
Hutchings M, Carlo-Stella C, Bachy E y col. Glofitamab step-up dosing induces high response rates in patients with hard-totreat refractory or relapsed non-Hodgkin lymphoma, Blood 136 (2020) 46-48. Nov (Supplement 1).
Schuster SJ, Bartlett NL, Assouline S y col. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood 2019; 134 (Supplement 1).
Matasar M,Chan Yoon Chea, Dok Hyun Yoon y col. Subcutaneous Mosunetuzumab in relapsed or refractory B-cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts. Blood 2020; 136 (Supplement 1) 45-46.
Phillips TJ, Olszewski AJ, Munoz J y col. Mosunetuzumab, a novel CD20/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood 2020;136 (Supplement 1) 37-38.
Bannerji R, Allan JN, Arnason JE y col. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood 2020;136 (Supplement 1) 42-43.
Hutchings M, Mous R, Clausen MR, P y col. Subcutaneous Epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data. Blood 2020;136 (Supplement 1) 45-46.
Pfeifer M, Zheng B, Erdmann T y col. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 2015; 29 (7) 1578-1586.
Palanca-Wessels MCA, Czuczman M, Salles G y col. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015; 16 (6) 704-715.
Sehn L, Herrera AF, Flowers CR y col. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 2020; 38 (2) 155-165.
National Comprehensive Cancer Network. B-Cell Lymphomas (Version 1.2022-2.2022).
Zammarchi F, Corbett S, Adams L y col. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 2018;131 (10) 1094-1105.
Hartley JA, Flynn MJ, Bingham JP y col. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci. Rep 2018; 8 (1) 1-10.
Caimi PF, Ai W, Alderuccio JP y col. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021; 22 (6) 790-800.
Chiarle R, Prolla A, Prolla G, Gong J, Thorbecke G, Inghirami G col. CD30 in normal and neoplastic cells. Clin. Immunol 1999; Vol. 90 157-164.
Jacobsen ED, Sharman JP, Oki Y y col. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015; 125 (9) 1394-1402.
Einsele H Borghaei H, Orlowski RZ y col. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer; 2020 Jul 15;126(14):3192-3201.
Salvaris R Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J. Pers. Med. 2021, 11 (5): 355.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar